19,190 reports of this reaction
3.3% of all SULFASALAZINE reports
#2 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #2 most commonly reported adverse reaction for SULFASALAZINE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 19,190 FDA adverse event reports linking SULFASALAZINE to RHEUMATOID ARTHRITIS. This represents approximately 3.3% of all 583,229 adverse event reports for this drug.
SULFASALAZINE has an overall safety score of 85 out of 100. Patients taking SULFASALAZINE who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is moderately reported among SULFASALAZINE users, representing a notable but not dominant share of adverse events.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for SULFASALAZINE:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 19,190 FDA reports for SULFASALAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 3.3% of all adverse event reports for SULFASALAZINE, making it one of the most commonly reported side effect.
If you experience rheumatoid arthritis while taking SULFASALAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.